LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of September 11, 2026, LLY stock price declined to $1,115.70 with 1,589,261 million shares trading.

LLY has a beta of 0.14, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.00 to the broad based SPY ETF.

LLY has a market cap of $994.49 billion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $23 billion in Revenue and $8.38 earnings per share. This beat revenue expectation by $3 billion and exceeded earnings estimates by $2.37.

In the last 3 years, LLY traded as high as $1,292.65 and as low as $516.57.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, SPY, VUG, XLV.

LLY has outperformed the market in the last year with a return of +48.4%, while the SPY ETF gained +17.4%. However, in the most recent history, LLY shares have underperformed the stock market with its stock returning -3.7% in the last 3 month period and -5.0% for the last 2 week period, while SPY has returned +3.9% and -0.7%, respectively.

LLY support price is $1,100.86 and resistance is $1,145.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.